AndroGel Dosing for Black and African Ancestry Patients: What the Evidence Shows

Does AndroGel Work Differently in Black and African Ancestry Patients?

The short answer is: the androgen axis itself does not operate through a fundamentally different mechanism in Black men, but several downstream variables differ enough to change clinical decision-making. Skin absorption rates, enzyme polymorphisms that govern DHT production, higher background rates of hypertension and CKD, and the specific comorbidity burden seen in this population all interact with testosterone replacement in ways that a one-size protocol misses.

What the Trials Actually Enrolled

Ethnicity-stratified pharmacokinetic data for AndroGel specifically are limited. The Testosterone Trials (T-Trials), the largest placebo-controlled testosterone RCT in older men (N=788, mean age 72), found that testosterone gel raised serum testosterone from a mean of 234 ng/dL to 454 ng/dL across the full cohort. [1] Black participants represented approximately 4% of that enrollment, a number too small for powered subgroup analysis. The FDA label for AndroGel 1.62% (NDA 202763) does not contain race-stratified pharmacokinetic tables, which means clinicians are extrapolating from population-level data. [2]

Skin Permeation and Transdermal Bioavailability

Transdermal testosterone absorption depends on stratum corneum thickness, sebaceous gland density, and regional blood flow. Published data on racial differences in stratum corneum permeability are mixed; a 2003 study by Berardesca and Maibach found no clinically significant difference in forearm permeation between Black and white subjects for several compounds, though regional variation was noted. [3] Practically, this means the standard 5% coefficient of variation in absorption seen in AndroGel pharmacokinetic studies likely applies across ancestry groups, and day-14 serum testosterone measurement remains the most reliable adjustment tool.

Pharmacogenomics: SRD5A2, CYP19A1, and AR CAG Repeat Length

This is where ancestry-specific biology becomes most clinically actionable. Three genetic variables affect how exogenous testosterone is converted, metabolized, and sensed at the receptor level.

SRD5A2 and DHT Conversion

The enzyme 5-alpha reductase type 2 (encoded by SRD5A2) converts testosterone to dihydrotestosterone (DHT), the primary androgen in prostate and skin tissue. The V89L variant (rs523349) reduces enzyme activity by roughly 30% in vitro. [4] Allele frequency data from the 1000 Genomes Project show the leucine allele (lower activity) is present in approximately 20 to 25% of men of African ancestry, compared with 30 to 40% in European ancestry populations, suggesting Black men on average may convert slightly more testosterone to DHT per unit dose. [4] The clinical consequence is a modestly higher DHT-to-testosterone ratio at equivalent AndroGel doses, which has implications for benign prostatic hyperplasia progression and scalp androgenicity but is unlikely to require routine dose reduction on this basis alone.

CYP19A1 and Estradiol Production

CYP19A1 encodes aromatase, the enzyme that converts testosterone to estradiol. Several single-nucleotide polymorphisms in CYP19A1 alter aromatase activity, and allele frequencies differ by ancestry. PharmGKB annotates CYP19A1 variants as influencing estradiol levels in men on testosterone therapy, though actionable genotype-guided dosing recommendations have not yet been formalized. [5] In practice, checking serum estradiol (LC-MS/MS preferred over immunoassay) at the 3-month visit is good standard-of-care for any man on testosterone gel, regardless of ancestry.

AR CAG Repeat Length and Androgen Sensitivity

The androgen receptor (AR) gene contains a polymorphic CAG trinucleotide repeat in exon 1. Shorter repeats correlate with greater transcriptional activity. Population studies consistently show that men of African ancestry carry shorter mean AR CAG repeat lengths (mean approximately 18 to 19 repeats) than men of European ancestry (mean approximately 21 to 22 repeats). [6] Shorter repeats predict greater androgen receptor sensitivity. This means Black men may achieve equivalent androgenic tissue effect at lower serum testosterone concentrations. Whether this justifies a lower target trough (say, 350 to 500 ng/dL rather than 400 to 700 ng/dL) is not established by RCT data, but the biology is worth factoring into shared decision-making with the patient.

Cardiovascular and Hematologic Risks in This Population

Hypertension Prevalence and Testosterone-Mediated Sodium Retention

The CDC reports that hypertension affects 57.1% of Black American men, compared with 43.6% of white American men. [7] Testosterone causes dose-dependent sodium and water retention through activation of the epithelial sodium channel (ENaC) in the renal collecting duct, a mechanism that can raise systolic blood pressure by 3 to 5 mmHg in susceptible men. [8] For a patient who already sits at 138/88 mmHg, that increment matters. The practical guidance: obtain a seated blood pressure measurement before initiating AndroGel, recheck at the 4-week titration visit, and apply the AHA/ACC threshold of 130/80 mmHg as the intervention trigger. [9] If blood pressure rises above 140/90 mmHg after initiating testosterone, optimize antihypertensive therapy before continuing titration.

A note on renin-angiotensin-aldosterone system (RAAS) pharmacology: Black patients as a group show attenuated blood pressure response to ACE inhibitors and ARBs as monotherapy compared with calcium channel blockers or thiazides, per JNC8 and ACC/AHA 2017 guidelines. [9] This is relevant because testosterone-induced volume expansion responds better to diuretic correction than to RAAS blockade alone. If antihypertensive intensification is needed after AndroGel initiation, a thiazide or calcium channel blocker is a more targeted choice.

Erythrocytosis and Sickle-Cell Trait

Testosterone stimulates erythropoiesis via EPO upregulation. Erythrocytosis (hematocrit above 54%) is the most common adverse effect requiring AndroGel dose reduction or interruption, occurring in roughly 5.9% of men in clinical trials. [2] Black men carry sickle-cell trait (HbAS) at a prevalence of roughly 8%, or 1 in 13. [10] Supraphysiologic testosterone-driven erythrocytosis in a man with HbAS could theoretically increase blood viscosity and sickle-related vascular risk, though direct clinical trial data on this interaction are absent. The prudent approach is a baseline hemoglobin electrophoresis or sickle-cell trait screen before AndroGel initiation if the patient's carrier status is unknown, then hematocrit checks at 3 months and 6 months.

If hematocrit exceeds 54%, the AndroGel prescribing information recommends stopping therapy until levels fall below 50%, then resuming at the next lower dose. [2] For a patient on 40.5 mg/day (1.62% gel), the step-down is 20.25 mg/day.

G6PD Deficiency: A Frequently Overlooked Variable

G6PD deficiency affects approximately 10 to 14% of men of African ancestry, making it the most common enzymopathy in this population. [11] While AndroGel itself is not a known oxidative trigger, supraphysiologic testosterone can increase reactive oxygen species production. The FDA label carries no G6PD contraindication for testosterone products, and no clinical trial has specifically examined this interaction. Screening for G6PD deficiency is not standard pre-AndroGel workup, but if a patient reports unexplained hemolytic episodes or has known G6PD deficiency, documenting this in the chart and maintaining testosterone levels in the mid-normal range (400 to 550 ng/dL) rather than the high-normal range is a defensible clinical choice.

CKD Risk and Renal Considerations

Black Americans develop CKD at a rate approximately 3-fold higher than white Americans, driven partly by hypertension, type 2 diabetes, and APOL1 high-risk genotypes. [12] Testosterone causes fluid retention, and in men with eGFR <45 mL/min/1.73m2, this retention can accelerate edema and worsen hypertension. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy recommends caution in men with severe renal impairment (eGFR <30) and does not provide race-specific dose adjustments. [13]

For men with eGFR 30 to 60 mL/min/1.73m2, starting AndroGel at the lowest available dose (20.25 mg/day for 1.62% gel, or 25 mg/day for 1% gel sachets) and titrating only after confirming stable renal function at 6 weeks is a conservative but justifiable approach. Sodium intake counseling and weight monitoring every 2 weeks during the first 3 months add a practical safety layer.

Practical Dosing Protocol for Black and African Ancestry Men

Standard FDA-approved AndroGel dosing applies as the starting point. The adjustments below reflect comorbidity burden and pharmacogenomic considerations rather than any mandate to dose differently based on race alone.

Starting Dose and Application

• AndroGel 1.62%: Begin at 40.5 mg (2 pump actuations) applied once daily to clean, dry, intact skin of the shoulders and upper arms.
• AndroGel 1%: Begin at 50 mg (one packet or 5 g gel) applied once daily to shoulders, upper arms, or abdomen.
• Application time: Morning application aligns with endogenous testosterone rhythm and allows afternoon serum draw at a stable trough.

Titration Schedule

Check serum total testosterone (morning, trough, at least 2 hours after application) at day 14 and again at day 28.

• If trough <400 ng/dL at day 14: Increase 1.62% gel to 60.75 mg (3 actuations) or 1% gel to 75 mg.
• If trough is 400 to 700 ng/dL: Maintain current dose.
• If trough >700 ng/dL: Reduce to next lower dose or discuss stopping therapy.

For a Black man with shorter AR CAG repeats and good symptom response at 400 ng/dL, there is no clinical rationale to chase 600 ng/dL. Symptom response (libido, fatigue scale, morning erections) is a co-equal endpoint alongside lab values.

Enhanced Monitoring Schedule

| Timepoint | Labs | Clinical check | |---|---|---| | Baseline | Total T, hematocrit, CBC, CMP (eGFR, electrolytes), PSA, lipid panel, BP | Weight, symptom questionnaire | | Week 2 | Morning total T | BP recheck | | Week 4 (dose titration) | Morning total T, BP | Symptom reassessment | | Month 3 | Total T, hematocrit, PSA, CMP | Weight, BP | | Month 6 | Hematocrit, BP | Symptom reassessment | | Annually | Full baseline panel | Shared decision-making on continuation |

If hypertension or CKD is present at baseline, add urine albumin-to-creatinine ratio and renal function at the 3-month visit.

What Guidelines Say (and What They Leave Out)

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism does not stratify dosing recommendations by race or ancestry. [13] It states: "We suggest that clinicians aim to achieve testosterone levels in the mid-normal range (400 to 700 ng/dL) and adjust doses based on testosterone levels, symptom response, and adverse effects." The guideline acknowledges that "the testosterone range associated with the best outcomes has not been established" and calls for shared decision-making.

The American Urological Association's 2018 guideline similarly applies uniform dosing language. [14] Neither guideline addresses SRD5A2 polymorphisms, AR CAG repeat variation, or APOL1 genotype in the context of TRT.

This is a significant evidence gap. The T-Trials, the most rigorous testosterone RCT available, enrolled predominantly non-Hispanic white men, with Black participants comprising roughly 4% of the sample. [1] Conclusions from that trial about cardiovascular outcomes, bone density, and sexual function cannot be cleanly extrapolated to Black men.

The AHA's 2024 Scientific Statement on cardiovascular risk in men on testosterone therapy notes that men with pre-existing cardiovascular disease or uncontrolled hypertension should be counseled carefully before initiating therapy, without race-specific guidance. [15] Given that Black men have higher baseline cardiovascular risk, this general caution applies with added weight.

Patient Communication Points

Shared decision-making works best when patients understand why monitoring is more frequent for them specifically. Three talking points that work in practice:

First, explain that AndroGel's blood-pressure effect is real and measurable. A 3 to 5 mmHg rise in systolic pressure sounds small but compounds existing risk. If the patient already takes a diuretic, adding testosterone does not automatically trigger a dose increase in the diuretic, but awareness helps.

Second, address sickle-cell trait proactively. Many Black men with HbAS have never been told they carry the trait. A baseline screen is quick, inexpensive, and gives both the clinician and patient actionable information before the drug is started.

Third, the goal is not the highest testosterone number. Symptom relief at 400 ng/dL is clinically equivalent to symptom relief at 650 ng/dL if the patient feels well. Men with shorter AR CAG repeats may genuinely feel better at lower trough levels, and chasing a higher number adds hematocrit risk with no documented benefit.

Key Drug Interactions Relevant to This Population

• Insulin / oral hypoglycemics: Testosterone improves insulin sensitivity. Black men have a higher prevalence of type 2 diabetes (approximately 12.1% vs. 7.5% in non-Hispanic white men per CDC). [16] Initiating AndroGel may lower fasting glucose by 10 to 20 mg/dL, requiring antidiabetic dose review at the 3-month visit.
• Warfarin: Testosterone potentiates warfarin's anticoagulant effect. Check INR within 2 weeks of initiating or changing AndroGel dose in any patient on warfarin.
• Corticosteroids: Combined fluid-retaining effects increase edema and hypertension risk. Use with caution and monitor blood pressure weekly for the first month.
• Cyclosporine: Case reports suggest testosterone may increase cyclosporine blood levels. In Black renal transplant patients (a group with higher post-transplant hypertension burden), this interaction warrants cyclosporine level checks within 2 weeks of AndroGel initiation.

PSA Monitoring in Black Men on AndroGel

Black men have a roughly 1.7-fold higher prostate cancer incidence than white men. [17] Testosterone therapy raises PSA modestly (median 0.30 ng/mL at 12 months in the T-Trials). [1] The Endocrine Society guideline recommends withholding testosterone in men with PSA above 4.0 ng/mL until urology evaluation. [13] For Black men, given their higher baseline risk, some experts apply the more conservative threshold of 3.0 ng/mL as a referral trigger, consistent with the approach used in high-risk prostate cancer screening programs. A confirmed PSA rise of more than 1.4 ng/mL over any 12-month period while on therapy warrants urology referral regardless of the absolute value.